CytoDyn submited protocol with FDA for phase 3 Registrational trial of leronlimab for critically ill COVID-19 population
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
On Nov. 17, 2021, Pacific Northwest National Laboratory (PNNL) announced researchers had compiled the most comprehensive road map…
On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…
On Jan. 27, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
On Dec. 31, 2020, CytoDyn announced a research manuscript submitted by Nicholas J. Agresti, M.D. had been accepted…
On Nov. 23, 2020, CytoDyn announced it had reached enrollment of 293 patients in its Phase 3 trial…
On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…
On Oct. 30, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced enrollment of volunteers in a phase…
On Oct. 30, 2020, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of…
On Oct. 28, 2020, Seagen announced the closing of a $1.0 billion equity investment by Merck in 5.0…
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
On Oct. 5, 2020, the Fred Hutchinson Cancer Research Center announced the opening of the COVID-19 Clinical Research…
On Sept. 29, 2020, the NIH announed that researchers had designed モminiproteinsヤ that bound tightly to the SARS-CoV-2…
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
On Sept. 23, 2020, Pascal Biosciences announced the Company had confirmed an earlier report that certain cannabinoids block…
On Sept. 14, 2020, at the Pacific Northwest National Laboratory (PNNL) reported that U.S. analysts monitoring global biothreats…
On Sept. 14, 2020, Pascal Biosciences and SoRSE Technology announced they had entered into a collaborative research agreement…
On Aug. 25, 2020, CytoDyn announced the Company had reached the requisite number of enrolled patients in its…
On Aug. 21, 2020, research by the University of Minnesota and the University of Washington found that every…
On Jul. 22, 20120, Evotec announced that the U.S. Department of Defense (DoD) had awarded its Seattle-based subsidiary,…
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
On Jul. 14, 2020, an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus…
On Jul. 8, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that it had created a registry…
On Jul. 8, 2020, the Fred Hutchinson Cancer Research Center was named the coordinating center for vaccine clinical…
On Jul. 3, 2020, CytoDyn announced it had signed an exclusive Distribution and Supply Agreement with American Regent…
On Apr. 17, 2020, the University of Washington Medicine announced that a new clinical blood test will be…
On Mar. 9, 2020, Winship Cancer Institute’s multiple myeloma team was awarded a $5 million grant from The…
On Feb. 21, 2020, Lundbeck announced that VYEPTI™ (eptinezumab-jjmr) had been approved by the U.S. Food and Drug…